ADVR release from 9-12-2000
otcnn.com
By Jack Burney
Published by OTCNN.com
09/12/2000 01:52 PM EST
Advanced Viral Research Corp. (OTCBB: ADVR) told scientists from The Advanced Viral Research Institute that its flagship drug, "Product R," inhibits the growth of adenovirus in cell culture. Adenovirus infections cause epidemic conjunctivitis ("pink eye"), upper and lower respiratory illness and gastroenteritis. There currently is no approved, non-toxic therapy for adenoviral infections.
ADVR scientists, led by Drs. Wenlin Huang, Jin Zhang, Qingping Jiang, Yuanen Ji, John Fisher and Shalom Z. Hirschman, presented their findings at the 38th Annual Meeting of the Infectious Diseases Society of America in New Orleans, and an abstract has been published in the July issue of Clinical Infectious Diseases (Vol. 31, page 320).
The company says that the discovery by its scientists of Product R's potential impact on adenoviral infection demonstrates Product R’s rich chemistry and pharmacology. ADVR’s research apparently shows that Product R has a direct anti-viral effect against adenovirus. In cell culture systems, the company claims that Product R inhibits adenovirus replication and viral EIA protein expression. The company cites these new findings as the scientific rationale for its efforts to develop an ophthalmic formulation of Product R for the potential treatment of pink eye. |
